Pricing Log in Create free account

CRISPR Therapeutics AG (CRSP) vs Dianthus Therapeutics, Inc. (DNTH)

CRISPR Therapeutics AG and Dianthus Therapeutics, Inc. are both Biotechnology companies. CRISPR Therapeutics AG and Dianthus Therapeutics, Inc. are of similar size ($4.7B and $4.6B). Dianthus Therapeutics, Inc. grew revenue faster over the last twelve months: −11.7% against −34.3%. CRISPR Therapeutics AG has the higher net margin (−1,812.1% vs −7,436.5%) and the higher return on invested capital (0.00% vs −36.6%). Across the 16 metrics below, CRISPR Therapeutics AG leads on 9 and Dianthus Therapeutics, Inc. on 7.

Valuation

Metric CRSP DNTH Biotechnology median
P/E n/m n/m 10.60
P/S 191.85 1,823.40 9.40
P/B 2.93 3.99 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 124.89 1,515.16 9.02
Earnings yield (9.50%) (4.62%) (32.88%)
Free cash flow yield (7.80%) (3.55%) (23.13%)

Profitability

Metric CRSP DNTH Biotechnology median
Gross margin 100.00% 100.00% 68.51%
Operating margin (2,114.75%) (8,683.89%) 0.00%
Net margin (1,812.07%) (7,436.50%) 0.00%
Free cash flow margin (1,496.56%) (6,469.87%) 0.00%
Return on equity (25.60%) (22.61%) (51.96%)
Return on assets (19.00%) (21.81%) (46.06%)
Return on invested capital 0.00% (36.55%) 0.00%

Growth

Metric CRSP DNTH Biotechnology median
Revenue growth (TTM) (34.34%) (11.70%) 6.76%
EPS growth (last fiscal year) (49.08%) (64.71%) 29.88%
Revenue growth, 5-year CAGR 37.31% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CRSP DNTH Biotechnology median
Debt to equity 0.36 0.00 0.00
Current ratio 16.21 30.02 4.97
Net debt to EBITDA 3.06 2.20 1.01

Dividend

Metric CRSP DNTH Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CRSP DNTH Biotechnology median
Market cap 4.71b 4.64b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack